Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Share This Webinar
About This Webinar
Regulatory guidelines require testing for bioprocess impurities. Reduction of bioprocess impurities to the lowest levels practical calls for sensitive and robust analytical methods. Cygnus offers a full menu of HCP ELISA kits and orthogonal testing services for all current cell expression systems utilized for viral vector manufacturing, ELISA for residual BSA and EndonucleaseGTP®, and viral clearance kits. Orthogonal HCP analytical methods include Antibody Affinity Extraction™ (AAE™), Mass Spectrometry and 2D PAGE. The integration of data from these orthogonal methods together with ELISA data provides a comprehensive analysis of HCP content, that will meet regulatory expectations.
Language:
English
Who can attend? Everyone
Featured Presenters
Director of Technical Marketing, Cygnus Technologies
Alla is passionate about helping Cygnus customers navigate the complexity of host cell protein and other bioprocess impurity analytics for viral vector clinical and commercial manufacturing.
Senior Director, Research and Development, Cygnus Technologies
David pioneered and commercialized novel BSL-1 compatible non-infectious MVM particles and kits enabling downstream purification scientists to study viral clearance throughout process development.
Technical Business Development Manager, West US
Angelo has been servicing the biopharma industry in California/Pacific Northwest for over 15yrs. with current emphasis on gene therapy and next-gen vaccine companies.
Technical Business Development Manager, Northeast US
Joel is a consummate Life Sciences professional who is dedicated to helping Biotech companies and organizations achieve their goals in the development of biological therapeutics.
Hosted By
The full session archive, available exclusively for attendees of the American Society of Gene & Cell Therapy's 23rd Annual Meeting, May 12-15, 2020.
Documents